Clinical Trials Logo

Jaundice, Neonatal clinical trials

View clinical trials related to Jaundice, Neonatal.

Filter by:

NCT ID: NCT06451900 Completed - Neonatal Jaundice Clinical Trials

Role of Fenofibrate in Neonatal Jaundice

Start date: July 1, 2023
Phase: Phase 4
Study type: Interventional

Fenofibrate appears to be an effective and safe drug for the treatment of neonatal hyperbilirubinemia. It has been proven that it decreases the duration of phototherapy and thus shortens the length of hospital stay. This study was performed to study the prophylactic role of fenofibrate in prevention of neonatal jaundice.

NCT ID: NCT06449508 Not yet recruiting - Jaundice, Neonatal Clinical Trials

The Effectiveness of Probiotics in Neonatal Jaundice

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Hyperbilirubinemia is a prevalent problem in babies that necessitates medical attention. Probiotic administration as adjuvant therapy may have a positive impact on the pathological neonatal unconjugated hyperbilirubinemia.

NCT ID: NCT06399146 Recruiting - Neonatal Jaundice Clinical Trials

Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana

BILIAPPBOT
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This project aims to test a novel smartphone application, Picterus, which provides a cheaper, patient-friendly, and more readily means of neonatal jaundice detection. For this purpose, the study aims to collect data from newborns with a broad range of bilirubin levels and high melanin content in a population in Botswana.

NCT ID: NCT06386731 Completed - Neonatal Jaundice Clinical Trials

Continuous Versus Intermittent Phototherapy in Treatment of Neonatal Jaundice

Start date: July 5, 2022
Phase: N/A
Study type: Interventional

One of the most common diseases in the neonatal period is indirect hyperbilirubinemia (IHB). After phototherapy was discovered accidentally in 1958, it has been used as the most effective treatment method for IHD for more than 60 years. Sources that provide phototherapy are developing rapidly technologically. However, there is no clearly defined usage table in the literature for applying phototherapy with faster effects and fewer side effects. In recent years, the use of intermittent phototherapy has been recommended with similar effectiveness. Phototherapy has significant side effects such as dehydration, diarrhea, chromosome breaks, retinal damage, skin rashes, hypocalcemia, thrombocytopenia. As phototherapy exposure decreases, its side effects decrease.In our study; We plan to find the most ideal method in the treatment of IHB by comparing intermittent PT with continuous phototherapy in terms of effectiveness. We aim to achieve the best bilirubin reduction and minimal side effects with less exposure to phototherapy.

NCT ID: NCT06372093 Completed - Jaundice, Neonatal Clinical Trials

Evaluation of Bilirubin Measurements in Newborns From Smartphone Digital Images in a Population in Botswana

Start date: March 16, 2023
Phase: N/A
Study type: Interventional

The general objective of this study is to evaluate the accuracy of a novel smartphone application for jaundice screening (Picterus Jaundice Pro) in a population with high melanin content in the skin. The specific objectives for this study are: i. To assess the correlation between bilirubin level measurements obtained by Picterus Jaundice Pro with Total Serum Bilirubin (TSB), and TcB, in newborns with high melanin content in the skin. ii. To determine the accuracy of Picterus Jaundice Pro in newborns with high melanin content in the skin.

NCT ID: NCT06346743 Not yet recruiting - Clinical trials for Physiological Neonatal Jaundice

Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Neonatal Jaundice.

Start date: April 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Neonatal jaundice has significant importance in neonatal morbidity and mortality world-wide. Though phototherapy has a relentless use in neonatal jaundice, its cumbersome side effects and the physical separation of baby from the mother eventually result as increase in days of hospitalization adding to the mental anguish of the parents. This study is conducted to observe the reduction of serum bilirubin level in neonates treated with Fenofibrate as an adjuvant to phototherapy in treatment of exaggerated physiological hyperbilirubinemia. After informed consent, single dose of Fenofibrate will be given to the group A (intervention group) and Group B (non-intervention) will only be given phototherapy. Then every 24-hourly sample for serum bilirubin will be sent for lab analysis, for 3 days. A randomized control trial is conducted and later on, the data will be analyzed in the SPSS 26. Quantitative variables like age will be presented as mean ± SD. Qualitative variables like gender will be presented as percentage and frequency. Comparison of two groups intervention group and non-intervention group, apply independent sample t-test. P value < 0.05 will be taken as significant. Limitation of the proposed study includes limited sample size, study population limited to only one hospital and no follow-up in plan. If the role of Fenofibrate is established in the management of exaggerated physiological hyperbilirubinemia in newborns, it will be beneficial to minimize the risk of the complications, rapid regression of hyperbilirubinemia & shortening the length of hospital stay.

NCT ID: NCT06341582 Recruiting - Neonatal Jaundice Clinical Trials

Prediction and Evaluation by ETCOc of Neonatal Hyperbilirubinemia Cohort

PREVENT
Start date: December 11, 2023
Phase:
Study type: Observational [Patient Registry]

The hemolytic disease of newborns (HDN) is one of the most significant risk factors for hyperbilirubinemia. Studies have shown that end-tidal carbon monoxide-corrected (ETCOc) correlated with the rate of bilirubin production in the body and thus can be a good surrogate to quantify hemolysis and identifying the high-risk infants. However, there is insufficient clinical evidence regarding the early prediction of hemolytic hyperbilirubinemia using ETCOc. This study hypothesizes that early postnatal ETCOc levels are significantly associated with the risk of hemolytic hyperbilirubinemia requiring treatments within 14 days after birth, and early postnatal ETCOc can be a good indicator for early prediction of hemolysis. In addition, the investigators aim to investigate the relationship between the characteristics of treatments for hyperbilirubinemia and ETCOc.

NCT ID: NCT06329843 Recruiting - Neonatal Jaundice Clinical Trials

Intermountain Inpatient Bilirubin Decision Accuracy Study Using Smartphone-based Measurements by Picterus Jaundice Pro

Start date: February 12, 2024
Phase:
Study type: Observational

The goal of this project is to evaluate the performance of Picterus Jaundice Pro in an American population, including preterm and term newborns and pre- and post- phototherapy.

NCT ID: NCT06276582 Recruiting - Jaundice, Neonatal Clinical Trials

Screening for Neonatal Jaundice With a Mobile Health Device: a Validation Study in Oaxaca, Mexico.

Start date: January 17, 2023
Phase: N/A
Study type: Interventional

The performance and accuracy of the smartphone application (app) Picterus Jaundice Pro (PicterusJP) will be validated by a cross-sectional study conducted in low resource settings in Mexico. Physics-based and machine learning-based models will be used to analyze the images obtained with the app and its performance will be compared.

NCT ID: NCT06227624 Completed - Neonatal Jaundice Clinical Trials

Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia

Start date: June 1, 2018
Phase: Phase 3
Study type: Interventional

This study aimed to determine the role of oral zinc in reducing the neonatal indirect hyperbilirubinemia if used concomitant with the standard phototherapy